Search results
Results from the WOW.Com Content Network
When approved, it was the most expensive medication available given in a single dose, costing over US$37,000 (€30,000) for the average dose. [ 10 ] [ 11 ] Compared with other monoclonal antibody treatments (many of which are well over $40,000 for a course of therapy), it may be considered cost effective.
AbbVie Inc's rheumatoid arthritis drug Humira and Roche Holding AG's cancer drug Rituxan topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion ...
Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. [18] It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia (in children and adults, but not recommended in elderly patients), rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura ...
Specialty drugs are now so expensive that they are leading to increases in insurance premiums. [58] Control of specialty drug prices will require research to identify effective policy options, which may include: decreasing regulation, limiting patent protection, allowing negotiation of drug prices by Medicare, or pricing drugs based on their ...
There are reports comparing these treatments in front of each other. Restricting the research only to relapses, it seems that alemtuzumab is the most cost effective [21] while anti-CD20 monoclonal antibodies (Rituxan, Ocrevus) have the better safety vs. efficacy profile [22]
rituximab/Rituxan December 2018 [158 ... small molecule drugs made up of a chemically based compound can be easily replicated and are considerably less expensive to ...
Cancer immunotherapy (immuno-oncotherapy) is the stimulation of the immune system to treat cancer, improving the immune system's natural ability to fight the disease. [1] It is an application of the fundamental research of cancer immunology (immuno-oncology) and a growing subspecialty of oncology.
From or to a drug trade name: This is a redirect from (or to) the trade name of a drug to (or from) the international nonproprietary name (INN).